<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00238251</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 70/03</org_study_id>
    <secondary_id>EU-20526</secondary_id>
    <nct_id>NCT00238251</nct_id>
  </id_info>
  <brief_title>Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases</brief_title>
  <official_title>Whole Brain Radiotherapy in Combination With Gefitinib (Iressa) or Temozolomide (Temodal) for Brain Metastases From Non-Small Lung Cancer (NSCLC) A Randomized Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Gefitinib may stop&#xD;
      the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used&#xD;
      in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor&#xD;
      cells, either by killing the cells or by stopping them from dividing. Giving radiation&#xD;
      therapy together with either gefitinib or temozolomide may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well giving radiation therapy&#xD;
      together with either gefitinib or temozolomide works in treating patients with non-small cell&#xD;
      lung cancer and brain metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the efficacy of whole-brain radiotherapy combined with either gefitinib or&#xD;
           temozolomide, in terms of overall survival, in patients with non-small cell lung cancer&#xD;
           and brain metastases.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the tolerability and toxicity of these regimens in these patients.&#xD;
&#xD;
        -  Compare the time to neurological disease progression, time to extracranial disease&#xD;
           progression, and time to overall disease progression, in patients treated with these&#xD;
           regimens.&#xD;
&#xD;
        -  Compare adverse events in patients treated with these regimens.&#xD;
&#xD;
        -  Compare cognitive function and quality of life of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, parallel-group, multicenter study. Patients are&#xD;
      stratified according to extracranial disease (yes vs no), number of brain metastases (1-3 vs&#xD;
      ≥ 4), prior chemotherapy (yes vs no), WHO performance status (0-1 vs 2), and participating&#xD;
      center. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients undergo whole-brain radiotherapy (WBRT) once daily on days 1-5 and 8-12&#xD;
           and receive oral gefitinib once daily on days 1-28. Gefitinib treatment repeats every 28&#xD;
           days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients undergo WBRT as in arm I and receive oral temozolomide once daily on&#xD;
           days 1-21. Temozolomide treatment repeats every 28 days in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline and on day 1 of courses 2, 3, and 5.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30-86 patients (15-43 per treatment arm) will be accrued for&#xD;
      this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>life-long</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to neurological progression</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to extracranial disease progression</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events as measured at completion of study treatment</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo whole-brain radiotherapy (WBRT) once daily on days 1-5 and 8-12 and receive oral gefitinib once daily on days 1-28. Gefitinib treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo WBRT as in arm I and receive oral temozolomide once daily on days 1-21. Temozolomide treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
    <description>Once daily during days 1-28</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <description>Once daily on days 1-21</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Whole brain radiotherapy</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung cancer AND newly&#xD;
             diagnosed brain metastases meeting 1 of the following criteria:&#xD;
&#xD;
               -  Multiple brain metastases&#xD;
&#xD;
               -  Single brain metastasis not amenable to potentially curative treatment&#xD;
&#xD;
          -  No advanced extracranial disease severely compromising vital functions and performance&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Hemoglobin &gt; 10 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN (5 times ULN in the presence of documented bone&#xD;
             metastases)&#xD;
&#xD;
          -  No unstable or uncompensated hepatic disease that would preclude study participation&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance ≥ 40 mL/min&#xD;
&#xD;
          -  No unstable or uncompensated renal disease that would preclude study participation&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No myocardial infarction within the past 3 months&#xD;
&#xD;
          -  No unstable or uncompensated cardiac disease that would preclude study participation&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No clinically active interstitial lung disease&#xD;
&#xD;
               -  Patients with chronic stable radiographic changes who are asymptomatic eligible&#xD;
&#xD;
          -  No other unstable or uncompensated respiratory disease that would preclude study&#xD;
             participation&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 12 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No nausea, vomiting, inability to swallow whole tablets/capsules, or malabsorption&#xD;
             syndrome that would preclude oral medication ingestion or absorption&#xD;
&#xD;
          -  No psychiatric disorder that would preclude giving informed consent or study&#xD;
             compliance&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus&#xD;
&#xD;
          -  No other medical condition that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior temozolomide&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent corticosteroids allowed provided dose has been stable or decreasing for ≥ 4&#xD;
             days before study entry&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior brain irradiation&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior gefitinib or erlotinib&#xD;
&#xD;
          -  More than 30 days since prior investigational clinical trial participation&#xD;
&#xD;
          -  No other concurrent experimental drugs&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No concurrent treatment with any of the following:&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Barbiturates&#xD;
&#xD;
               -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
               -  Other enzyme-inducing anti-epileptic drugs or tuberculostatic treatments&#xD;
&#xD;
               -  Any drug that contraindicates administration with study drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gianfranco Pesce, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger Stupp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oncology Institute of Southern Switzerland</name>
      <address>
        <city>Bellinzona</city>
        <zip>CH-6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Pesce GA, Klingbiel D, Ribi K, Zouhair A, von Moos R, Schlaeppi M, Caspar CB, Fischer N, Anchisi S, Peters S, Cathomas R, Bernhard J, Kotrubczik NM, D'Addario G, Pilop C, Weber DC, Bodis S, Pless M, Mayer M, Stupp R. Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). Eur J Cancer. 2012 Feb;48(3):377-84. doi: 10.1016/j.ejca.2011.10.016. Epub 2011 Nov 15.</citation>
    <PMID>22093943</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>October 12, 2005</study_first_submitted>
  <study_first_submitted_qc>October 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2005</study_first_posted>
  <last_update_submitted>June 4, 2012</last_update_submitted>
  <last_update_submitted_qc>June 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>tumors metastatic to brain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

